Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Active, not recruiting · NCT04375228 · Registry updated 2026-08-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) | Advanced Solid Tumor; Immune-related Adverse Events | Active, not recruiting | Phase 2 | 2026-08-03 | NCT04375228 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Columbia University | 375 |
| Genentech, Inc. | 221 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center | New York | United States | 1 |
| Johns Hopkins | Baltimore | United States | 6 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 16 |